Chemotherapy Induced Thrombocytopenia Therapeutics Market, By Drug Class, By Route of Administration, By Distribution Channel, and By Region

Description

The global chemotherapy-induced thrombocytopenia therapeutics market is estimated to be valued at US$ 1,531.3 Mn in 2023, and is expected to exhibit a CAGR of 5% during the forecast period (2023-2030).

Report Coverage		Report Details
Base Year:	2022	Market Size in 2023:	US$ 1,531.3 Mn
Historical Data for:	2018 to 2021	Forecast Period:	2023 - 2030
Forecast Period 2023 to 2030 CAGR:	5.00%	2030 Value Projection:	US$ 2,154.6 Mn

Figure 1. Global Chemotherapy-induced Thrombocytopenia Therapeutics Market Share (%), By Drug Class, 2023

Chemotherapy Induced Thrombocytopenia Therapeutics Market - IMG1

Chemotherapy-induced Thrombocytopenia (CIT) is a prevalent medical condition associated with reduced chemotherapy doses, treatment interruptions, bleeding complications, and unfavorable outcomes in cancer patients. Currently, there exists a lack of well-defined guidelines for the prevention and management of CIT. In response to this challenge, thrombopoietin (TPO) replacement therapy has been developed and employed as an approach to address CIT by stimulating the production of megakaryocytes and expediting platelet generation. Despite platelet transfusions being the primary approach to managing severe CIT in cancer patients, there remain substantial unmet needs. These include persistently high rates of bleeding events and the necessity for adjustments or delays in anticancer therapy dosages.

Market Dynamics

The increasing number of pipeline products for the treatment of chemotherapy-induced thrombocytopenia is expected to drive the market growth. For instance, Nplate (Amgen Inc.) is a thrombopoietin receptor agonist (TPO-RA). It is being investigated in phase 3 for the treatment of chemotherapy-induced thrombocytopenia (CIT).

Thus, rising number of lead candidates in late phase clinical trial having the potential to gain regulatory approval is providing robust opportunities for pharmaceutical manufacturers to launch novel drugs for the treatment of CIT.

For instance, on October 19, 2020, Institute of Hematology & Blood Diseases Hospital initiated the single-arm study to evaluate the safety and efficacy of eltrombopag to treat chemotherapy-induced thrombocytopenia. The study is under Phase II trial and is expected to complete by December 2023.

Key features of the study:

This report provides an in-depth analysis of the global chemotherapy-induced thrombocytopenia therapeutics market and provides market size (US$ Mn) and Compound Annual Growth Rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year
It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global chemotherapy-induced thrombocytopenia therapeutics market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
The key companies covered as a part of this study include Amgen, Inc., Novartis AG, Pfizer Inc., Swedish Orphan Biovitrum AB, Jiangsu HengRui Medicine Co., Ltd., Teva Pharmaceutical Industries Ltd., and Mylan N.V.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global chemotherapy-induced thrombocytopenia therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global chemotherapy-induced thrombocytopenia therapeutics market

Global Chemotherapy-induced Thrombocytopenia Therapeutics Market Detailed Segmentation:

By Drug Class:
- Thrombopoietin Receptor Agonists
- Thrombopoietic Agents
- Others
By Route of Administration:
- Oral
- Injectable
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
Company Profiles
- Amgen, Inc.
- Novartis AG
- Pfizer Inc.
- Swedish Orphan Biovitrum AB
- Jiangsu HengRui Medicine Co., Ltd.
- Teva Pharmaceutical Industries Ltd.
- Mylan N.V.

Product Code: CMI4332

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Drug Class
- Market Snippet, By Route of Administration
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Market Trend
Key Developments
Regulatory Scenario
PEST Analysis
Pipeline Analysis
Acquisition and Collaboration Scenario

4. Global Chemotherapy-induced Thrombocytopenia Therapeutics Market - COVID-19 Impact Analysis

COVID-19 Epidemiology
Overall Impact on the Healthcare Sector
Total Impact of COVID-19 on the Global Chemotherapy-induced Thrombocytopenia Therapeutics Market
Supply and Demand Analysis

5. Global Chemotherapy-induced Thrombocytopenia Therapeutics Market, By Drug Class, 2018-2030, (US$ Mn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
Thrombopoietin Receptor Agonists
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends
Thrombopoietin Receptor Agonists
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends

6. Global Chemotherapy-induced Thrombocytopenia Therapeutics Market, By Route of Administration, 2018-2030, (US$ Mn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends
Injectable
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends

7. Global Chemotherapy-induced Thrombocytopenia Therapeutics Market, By Distribution Channel, 2018-2030, (US$ Mn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends

8. Global Chemotherapy-induced Thrombocytopenia Therapeutics Market, By Region, 2018-2030, (US$ Mn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Mn)
U.S.
Canada
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Mn)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Mn)
China
Japan
India
ASEAN
Australia
South Korea
Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Mn)
Brazil
Mexico
Argentina
Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Mn)
GCC
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2018-2030, (US$ Mn)
North Africa
Central Africa
South Africa

9. Competitive Landscape

Heat Map Analysis
Company Profiles
- Amgen, Inc.
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Novartis AG
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Pfizer Inc.
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Swedish Orphan Biovitrum AB
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Jiangsu HengRui Medicine Co., Ltd.
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Teva Pharmaceutical Industries Ltd.
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Mylan N.V.
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies

10. Section

References
Research Methodology
About us and Sales Contact